AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 256 GBX 0.12% Market Closed
Market Cap: 159B GBX
Have any thoughts about
AstraZeneca PLC?
Write Note

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is 16 596.56 GBX. Compared to the current market price of 10 256 GBX, AstraZeneca PLC is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
Base Case
16 596.56 GBX
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
25
Median 3Y
4.6
Median 5Y
4.7
Industry
2.5
Forward
0
vs History
87
vs Industry
11
Median 3Y
37.2
Median 5Y
38.5
Industry
21.8
Forward
0.2
vs History
98
vs Industry
17
Median 3Y
21.8
Median 5Y
24
Industry
16.1
vs History
66
vs Industry
15
Median 3Y
38.9
Median 5Y
29.7
Industry
23.8
vs History
87
vs Industry
11
Median 3Y
5.4
Median 5Y
5.9
Industry
2.1
vs History
41
vs Industry
5
Median 3Y
53.4
Median 5Y
49.1
Industry
2.7
Forward
0.5
vs History
41
vs Industry
4
Median 3Y
65
Median 5Y
61
Industry
5.2
vs History
33
vs Industry
2
Median 3Y
166.2
Median 5Y
161.2
Industry
13.5
Forward
1.4
vs History
77
vs Industry
1
Median 3Y
257.7
Median 5Y
275.6
Industry
16.8
Forward
1.6
vs History
69
vs Industry
1
Median 3Y
240.5
Median 5Y
244.9
Industry
15.2
vs History
65
vs Industry
1
Median 3Y
381.5
Median 5Y
410.5
Industry
19.3
vs History
11
vs Industry
4
Median 3Y
30.8
Median 5Y
29.9
Industry
1.9

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
UK
AstraZeneca PLC
LSE:AZN
Average P/S: 382 947.6
4.1
35%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
UK
AstraZeneca PLC
LSE:AZN
Average P/E: 31.6
31
177%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBITDA: 436.9
169.2
64%
2.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBIT: 1 869
253.5
131%
1.9
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Discover More
Back to Top